1
|
Fujimoto T. [A Case of Intestinal Obstruction Due to an Internal Hernia in the Mesenteric Defect after Laparoscopic Resection of Transverse Colon]. Gan To Kagaku Ryoho 2024; 51:436-438. [PMID: 38644314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/23/2024]
Abstract
72-year-old man who was diagnosed with transverse colon cancer cT3N1aM0, Stage Ⅲb, and underwent laparoscopic- assisted resection of the transverse colon. Postoperatively, the patient was discharged from the hospital after 24 days due to complications such as paralytic ileus and intra-abdominal abscess caused by prolonged intestinal congestion. On postoperative day 91, the patient developed abdominal pain and vomiting at home, and was rushed to our hospital on the same day. Abdominal CT showed that an internal hernia had formed in the mesenteric defect after resection of the transverse colon, which was suspected to have caused obstruction of the small intestine. After adequate preoperative decompression of the intestinal tract, a laparoscopic surgery was performed on the 9th day. The operative findings were that the jejunum(100- 160 cm from the Treitz ligament)had strayed into the mesenteric defect of the transverse colon, resulting in an internal hernia. After the internal hernia was repaired laparoscopically, the mesenteric defect was closed with a 3-0 V-Loc(non- absorbable). The patient had a good postoperative course and was discharged home 6 days after surgery.
Collapse
|
2
|
Wakamiya T, Fujimoto T, Endo T, Nishioka S, Yokoyama N, Yamashita S, Kikkawa K, Hyodo Y, Ishimura T, Kohjimoto Y, Hara I, Fujisawa M. Myosteatosis as a novel predictor of new-onset diabetes mellitus after kidney transplantation. Int J Urol 2024; 31:39-44. [PMID: 37743534 DOI: 10.1111/iju.15304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2023] [Accepted: 09/07/2023] [Indexed: 09/26/2023]
Abstract
OBJECTIVES We evaluate the effect of myosteatosis on new-onset diabetes mellitus after kidney transplantation. METHODS Consecutive patients who had renal transplant between 2006 and 2021 were reviewed, and 219 patients were finally included. Psoas muscle index was used to evaluate sarcopenia and average total psoas density (calculated by computed tomography before surgery) for myosteatosis. We used Cox proportional regression analyses in investigation of whether skeletal muscle depletion before surgery inclusive of sarcopenia and myosteatosis is a new additional predictor of new-onset diabetes mellitus. RESULTS Median recipient age and body mass index were 45 years and 21.1 kg/m2 , respectively, and 123 patients (56%) were male. Preoperative impaired glucose tolerance was present in 58 patients (27%) and new-onset diabetes mellitus in 30 patients (14%), with median psoas muscle index of 6 cm2 /m2 and average total psoas density of 41 Hounsfield Unit. In multivariate analysis, significant risk factors were body mass index ≥25 kg/m2 (p < 0.01), impaired glucose tolerance (p < 0.01), and average total psoas density < 41.9 Hounsfield Unit (p = 0.03). New-onset diabetes mellitus had incidence rates of 3.7% without risk factors, 10% with a single risk factor, 33% with two, and 60% with three. Patients with new-onset diabetes mellitus were effectively stratified by the number of risk factors (p < 0.01). CONCLUSIONS Myosteatosis could be a new risk factor used to predict new-onset diabetes mellitus.
Collapse
Affiliation(s)
- Takahito Wakamiya
- Department of Urology, Wakayama Medical University, Wakayama, Japan
- Division of Urology, Department of Surgery, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Takuya Fujimoto
- Division of Urology, Department of Surgery, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Takahito Endo
- Division of Urology, Department of Surgery, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Shun Nishioka
- Division of Urology, Department of Surgery, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Naoki Yokoyama
- Division of Urology, Department of Surgery, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | | | - Kazuro Kikkawa
- Department of Urology, Wakayama Medical University, Wakayama, Japan
| | - Yoji Hyodo
- Division of Urology, Department of Surgery, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Takeshi Ishimura
- Division of Urology, Department of Surgery, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Yasuo Kohjimoto
- Department of Urology, Wakayama Medical University, Wakayama, Japan
| | - Isao Hara
- Department of Urology, Wakayama Medical University, Wakayama, Japan
| | - Masato Fujisawa
- Division of Urology, Department of Surgery, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| |
Collapse
|
3
|
Fujimoto T, Maeda N, Ioka T, Nagano H. [A Case of HER2-Positive Advanced Breast Cancer Who Was Able to Start and Continue Chemotherapy Despite Liver Damage Due to Diffuse Liver Metastasis]. Gan To Kagaku Ryoho 2023; 50:1739-1741. [PMID: 38303191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2024]
Abstract
49-year-old woman, who diagnosed advanced breast cancer with, ER-positive, HER2-positive, T4bN1M1, Stage Ⅳ. At the time of initial diagnosis, liver damage equivalent to Child-Pugh classification C due to diffuse liver metastasis was observed, but trastuzumab/pertuzumab(HP)and paclitaxel(PTX)adjusted according to liver function were administered every 3 weeks, resulting in rapid improvement of liver function, PR of the primary tumor(90% reduction), PR of the liver metastases(70% reduction), and improvement of tumor markers. Currently, chemotherapy has been switched to docetaxel (DTX)due to peripheral neuropathy caused by PTX, and treatment is continuing. In the case of HER2-positive breast cancer, good disease control may be achieved with aggressive treatment and intervention under dose adjustment and careful systemic management, even in the setting of liver injury.
Collapse
|
4
|
Fujimoto T, Hyodo Y, Ishimura T, Tashiro Y, Endo T, Nisioka S, Yokoyama N, Yamamoto K, Yano I, Fujisawa M. Association of Alpha-Actinin-3 Polymorphism With Sarcopenia in Kidney Transplant Recipients. Transplant Proc 2023:S0041-1345(23)00150-1. [PMID: 37037724 DOI: 10.1016/j.transproceed.2023.03.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Accepted: 03/13/2023] [Indexed: 04/12/2023]
Abstract
BACKGROUND Sarcopenia is defined as the loss of skeletal muscle mass and function and is associated with increased mortality. Certain genetic polymorphisms represent risk factors used to assess the incidence of sarcopenia; however, few studies have evaluated the association between genetic polymorphisms and sarcopenia after kidney transplantation (KTx). We examined single-nucleotide polymorphisms (SNPs) in the genes involved in sarcopenia after KTx. METHODS Sixty-five patients who underwent KTx were enrolled in this study. We used the psoas mass index (PMI; the cross-sectional area of the bilateral psoas muscle/height) as a surrogate marker for assessing the extent of sarcopenia. We determined the PMI before KTx and 1 year after KTx, and we identified 5 SNPs in 5 genes associated with sarcopenia in the general population. Finally, the link between the changes in PMI 1 year after KTx and each SNP was examined. RESULTS The median PMI before KTx and 1 year after KTx was 7.4 (4.6-13.2) and 7.0 (3.6-13.6), respectively. The PMI decreased in 43 patients (66.2%). The alpha-actinin-3 rs1815739 genotype was associated with changes in PMI; the distribution of CT+TT genotypes in the PMI decrease group was significantly higher than that of the CC genotype (odds ratio, 4.23; 95% CI 0.05-0.97; P = 0.025). Moreover, the T allele frequency was significantly higher in the PMI decrease group than in the PMI increase group (odds ratio, 2.34; 95% CI 0.18-0.950; P = 0.025). CONCLUSION The alpha-actinin-3 rs1815739 genotype may represent a genetic risk factor for sarcopenia after KTx.
Collapse
Affiliation(s)
- Takuya Fujimoto
- Division of Urology, Department of Surgery Related, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yoji Hyodo
- Division of Urology, Department of Surgery Related, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| | - Takeshi Ishimura
- Division of Urology, Department of Surgery Related, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yuki Tashiro
- Division of Urology, Department of Surgery Related, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Takahito Endo
- Division of Urology, Department of Surgery Related, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Shun Nisioka
- Division of Urology, Department of Surgery Related, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Naoki Yokoyama
- Division of Urology, Department of Surgery Related, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | | | - Ikuko Yano
- Department of Pharmacy, Kobe University Hospital, Kobe, Japan
| | - Masato Fujisawa
- Division of Urology, Department of Surgery Related, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
5
|
Kitphaitun S, Fujimoto T, Ochi Y, Nomura K. Effect of Borate Cocatalysts toward Activity and Comonomer Incorporation in Ethylene Copolymerization by Half-Titanocene Catalysts in Methylcyclohexane. ACS Org Inorg Au 2022; 2:386-391. [PMID: 36855669 PMCID: PMC9955119 DOI: 10.1021/acsorginorgau.2c00020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Revised: 07/15/2022] [Accepted: 07/22/2022] [Indexed: 11/30/2022]
Abstract
Ethylene copolymerizations with 2-methyl-1-pentene, 1-dodecene (DD), vinylcyclohexane (VCH), [Me2Si(C5Me4)(N t Bu)]TiCl2 (1), Cp*TiMe2(O-2,6- i Pr2-4-RC6H2) [R = H (2), SiEt3 (3)]-borate, and [A(H)]+[BAr4]- [Ar = C6F5; A(H)+ = N+(H)Me(n-C18H37)2, N+(H)(CH2CF3)(n-C18H37)2, HO+(n-C14H29)2·O(n-C14H29)2, HO+(n-C16H33)2·O(n-C16H33)2; Ar = C10F7, A(H)+ = HO+(n-C14H29)2·O(n-C14H29)2 (B5), N+(H)(CH2CF3)(n-C18H37)2] catalyst systems conducted in methylcyclohexane (MCH) exhibited better comonomer incorporation than those conducted in toluene (in the presence of methylaluminoxane (MAO) or borate cocatalysts). The activity was affected by the borate cocatalyst and 1,3-B5 catalyst systems in MCH and showed the highest activity in the ethylene copolymerizations with VCH and DD.
Collapse
Affiliation(s)
- Suphitchaya Kitphaitun
- Department
of Chemistry, Graduate School of Science, Tokyo Metropolitan University, 1-1 Minami Osawa, Hachioji,
Tokyo 192-0376, Japan
| | - Takuya Fujimoto
- AGC
Inc., Yokohama Technical Center, 1-1, Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
| | - Yosuke Ochi
- AGC
Inc., Yokohama Technical Center, 1-1, Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
| | - Kotohiro Nomura
- Department
of Chemistry, Graduate School of Science, Tokyo Metropolitan University, 1-1 Minami Osawa, Hachioji,
Tokyo 192-0376, Japan,
| |
Collapse
|
6
|
Takemori T, Kawamoto T, Hara H, Fukase N, Fujiwara S, Fujita I, Fujimoto T, Morishita M, Kitayama K, Yahiro S, Miyamoto T, Saito M, Sugaya J, Hayashi K, Kawashima H, Torigoe T, Nakamura T, Kondo H, Wakamatsu T, Watanuki M, Kito M, Tsukushi S, Nagano A, Outani H, Toki S, Nishimura S, Kobayashi H, Watanabe I, Demizu Y, Sasaki R, Fukumoto T, Niikura T, Kuroda R, Akisue T. Clinical Outcome of Patients with Pelvic and Retroperitoneal Bone and Soft Tissue Sarcoma: A Retrospective Multicenter Study in Japan. Cancers (Basel) 2022; 14:cancers14123023. [PMID: 35740688 PMCID: PMC9221521 DOI: 10.3390/cancers14123023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Revised: 06/17/2022] [Accepted: 06/18/2022] [Indexed: 01/25/2023] Open
Abstract
Simple Summary We aimed to clarify the clinical outcomes of patients with pelvic and retroperitoneal bone and soft tissue sarcoma. The 3-year overall survival (OS), local control (LC) rate, and progression-free survival (PFS) were 71.7%, 79.1%, and 48.6%, respectively. The most influential poor prognostic factor for OS was distant metastasis, and for PFS, this was higher age (≥60 years). Larger primary tumor size (≥10 cm) was the only poor prognostic factor for LC. In the histological analysis, osteosarcoma showed significantly worse OS and PFS than other sarcomas in the pelvis and retroperitoneum. Abstract This study aimed to retrospectively analyze the clinical outcomes of patients with pelvic and retroperitoneal bone and soft tissue sarcoma (BSTS). Overall, 187 patients with BSTS in the pelvis and retroperitoneal region treated at 19 specialized sarcoma centers in Japan were included. The prognostic factors related to overall survival (OS), local control (LC), and progression-free survival (PFS) were evaluated. The 3-year OS and LC rates in the 187 patients were 71.7% and 79.1%, respectively. The 3-year PFS in 166 patients without any distant metastases at the time of primary tumor diagnosis was 48.6%. Osteosarcoma showed significantly worse OS and PFS than other sarcomas of the pelvis and retroperitoneum. In the univariate analyses, larger primary tumor size, soft tissue tumor, distant metastasis at the time of primary tumor diagnosis, P2 location, chemotherapy, and osteosarcoma were poor prognostic factors correlated with OS. Larger primary tumor size, higher age, soft tissue tumor, chemotherapy, and osteosarcoma were poor prognostic factors correlated with PFS in patients without any metastasis at the initial presentation. Larger primary tumor size was the only poor prognostic factor correlation with LC. This study has clarified the epidemiology and prognosis of patients with pelvic and retroperitoneal BSTS in Japan.
Collapse
Affiliation(s)
- Toshiyuki Takemori
- Department of Orthoapedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan; (T.T.); (H.H.); (N.F.); (S.F.); (K.K.); (S.Y.); (T.M.); (T.N.); (R.K.); (T.A.)
- Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi 673-8558, Japan; (I.F.); (T.F.); (M.M.)
| | - Teruya Kawamoto
- Department of Orthoapedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan; (T.T.); (H.H.); (N.F.); (S.F.); (K.K.); (S.Y.); (T.M.); (T.N.); (R.K.); (T.A.)
- Division of Orthopaedic Surgery, Kobe University Hospital, International Clinical Cancer Research Center, Kobe 650-0047, Japan
- Correspondence: ; Tel.: +81-783825985
| | - Hitomi Hara
- Department of Orthoapedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan; (T.T.); (H.H.); (N.F.); (S.F.); (K.K.); (S.Y.); (T.M.); (T.N.); (R.K.); (T.A.)
| | - Naomasa Fukase
- Department of Orthoapedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan; (T.T.); (H.H.); (N.F.); (S.F.); (K.K.); (S.Y.); (T.M.); (T.N.); (R.K.); (T.A.)
| | - Shuichi Fujiwara
- Department of Orthoapedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan; (T.T.); (H.H.); (N.F.); (S.F.); (K.K.); (S.Y.); (T.M.); (T.N.); (R.K.); (T.A.)
| | - Ikuo Fujita
- Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi 673-8558, Japan; (I.F.); (T.F.); (M.M.)
| | - Takuya Fujimoto
- Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi 673-8558, Japan; (I.F.); (T.F.); (M.M.)
| | - Masayuki Morishita
- Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi 673-8558, Japan; (I.F.); (T.F.); (M.M.)
| | - Kazumichi Kitayama
- Department of Orthoapedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan; (T.T.); (H.H.); (N.F.); (S.F.); (K.K.); (S.Y.); (T.M.); (T.N.); (R.K.); (T.A.)
| | - Shunsuke Yahiro
- Department of Orthoapedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan; (T.T.); (H.H.); (N.F.); (S.F.); (K.K.); (S.Y.); (T.M.); (T.N.); (R.K.); (T.A.)
| | - Tomohiro Miyamoto
- Department of Orthoapedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan; (T.T.); (H.H.); (N.F.); (S.F.); (K.K.); (S.Y.); (T.M.); (T.N.); (R.K.); (T.A.)
| | - Masanori Saito
- Department of Orthopaedic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan;
| | - Jun Sugaya
- Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan;
| | - Katsuhiro Hayashi
- Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-8641, Japan;
| | - Hiroyuki Kawashima
- Division of Orthopaedic Surgery, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan;
| | - Tomoaki Torigoe
- Department of Orthopaedic Oncology and Surgery, Saitama Medical University International Medical Center, Hidaka 350-1298, Japan;
| | - Tomoki Nakamura
- Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan;
| | - Hiroya Kondo
- Department of Orthopaedic Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama University, Okayama 700-8558, Japan;
| | - Toru Wakamatsu
- Department of Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka 541-8567, Japan;
| | - Munenori Watanuki
- Department of Orthopaedic Surgery, School of Medicine, Tohoku University, Sendai 980-8574, Japan;
| | - Munehisa Kito
- Department of Orthopaedic Surgery, School of Medicine, Shinshu University, Matsumoto 390-8621, Japan;
| | - Satoshi Tsukushi
- Department of Orthopaedic Surgery, Aichi Cancer Center Hospital, Nagoya 464-0021, Japan;
| | - Akihito Nagano
- Department of Orthopaedic Surgery, Gifu University, Gifu 501-1194, Japan;
| | - Hidetatsu Outani
- Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan;
| | - Shunichi Toki
- Department of Orthopaedics, Institute of Biomedical Sciences, Graduate School, Tokushima University, Tokushima 770-8503, Japan;
| | - Shunji Nishimura
- Department of Orthopaedic Surgery, Kindai University Hospital, Osaka-Sayama 589-8511, Japan;
| | - Hiroshi Kobayashi
- Department of Orthopaedic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan;
| | - Itsuo Watanabe
- Department of Orthopaedic Surgery, Tokyo Dental College Ichikawa General Hospital, Ichikawa 272-8513, Japan;
| | - Yusuke Demizu
- Department of Radiation Oncology, Hyogo Ion Beam Medical Center Kobe Proton Center, Kobe 650-0047, Japan;
| | - Ryohei Sasaki
- Division of Radiation Oncology, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan;
| | - Takumi Fukumoto
- Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan;
| | - Takahiro Niikura
- Department of Orthoapedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan; (T.T.); (H.H.); (N.F.); (S.F.); (K.K.); (S.Y.); (T.M.); (T.N.); (R.K.); (T.A.)
| | - Ryosuke Kuroda
- Department of Orthoapedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan; (T.T.); (H.H.); (N.F.); (S.F.); (K.K.); (S.Y.); (T.M.); (T.N.); (R.K.); (T.A.)
| | - Toshihiro Akisue
- Department of Orthoapedic Surgery, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan; (T.T.); (H.H.); (N.F.); (S.F.); (K.K.); (S.Y.); (T.M.); (T.N.); (R.K.); (T.A.)
- Department of Rehabilitation Science, Graduate School of Health Sciences, Kobe University, Kobe 654-0142, Japan
| |
Collapse
|
7
|
Yahiro S, Fujimoto T, Fujita I, Takai T, Sakuma T, Sudo T, Morishita M, Takigami S, Kawamoto T, Hara H, Akisue T, Kuroda R, Hirose T. Proximal-type epithelioid sarcoma in pubic region expressing L-type amino acid transporter 1: A case report. SAGE Open Med Case Rep 2022; 10:2050313X211067917. [PMID: 35024147 PMCID: PMC8743976 DOI: 10.1177/2050313x211067917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2021] [Accepted: 12/02/2021] [Indexed: 11/15/2022] Open
Abstract
Proximal-type epithelioid sarcoma is an aggressive malignant soft-tissue neoplasm, a “proximal” variant of epithelioid sarcoma, resistant to multimodal therapy and involved in early tumor-related death. Pertinent treatments are, therefore, continually being explored. A 24-year-old woman with nonmetastatic proximal-type epithelioid sarcoma, originating subcutaneously on the right side of the vulva, underwent surgical resection; the lesion recurred, however, leading to death 3 months after the second surgery. Here described is a case of proximal-type epithelioid sarcoma expressing L-type amino acid transporter 1 (LAT1) that transports essential amino acids and p-borono-L-phenylalanine (BPA)—the chemical compound used in boron neutron capture therapy (BNCT)—and is highly expressed in many malignant tumors. Recently, LAT1 has drawn attention, and relevant treatments have been studied—LAT1 inhibitor and BNCT. LAT1 expression in proximal-type epithelioid sarcoma may lead to cogent treatments for the disease.
Collapse
Affiliation(s)
- Shunsuke Yahiro
- Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi, Japan.,Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Takuya Fujimoto
- Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi, Japan.,Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Ikuo Fujita
- Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi, Japan
| | - Toshihiro Takai
- Department of Dermatology, Hyogo Cancer Center, Akashi, Japan
| | - Toshiko Sakuma
- Department of Pathology, Hyogo Cancer Center, Akashi, Japan
| | - Tamotsu Sudo
- Section of Translational Research, Hyogo Cancer Center, Akashi, Japan
| | | | - Shunsaku Takigami
- Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi, Japan
| | - Teruya Kawamoto
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.,Division of Orthopaedic Surgery, Kobe University Hospital International Clinical Cancer Research Center, Kobe, Japan
| | - Hitomi Hara
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Toshihiro Akisue
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Ryosuke Kuroda
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | | |
Collapse
|
8
|
Mizuta S, Otaki H, Ishikawa T, Makau JN, Yamaguchi T, Fujimoto T, Takakura N, Sakauchi N, Kitamura S, Nono H, Nishi R, Tanaka Y, Takeda K, Nishida N, Watanabe K. Lead Optimization of Influenza Virus RNA Polymerase Inhibitors Targeting PA-PB1 Interaction. J Med Chem 2021; 65:369-385. [PMID: 34905383 DOI: 10.1021/acs.jmedchem.1c01527] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Influenza viruses are responsible for contagious respiratory illnesses in humans and cause seasonal epidemics and occasional pandemics worldwide. Previously, we identified a quinolinone derivative PA-49, which inhibited the influenza virus RNA-dependent RNA polymerase (RdRp) by targeting PA-PB1 interaction. This paper reports the structure optimization of PA-49, which resulted in the identification of 3-((dibenzylamino)methyl)quinolinone derivatives with more potent anti-influenza virus activity. During the optimization, the hit compound 89, which was more active than PA-49, was identified. Further optimization and scaffold hopping of 89 led to the most potent compounds 100 and a 1,8-naphthyridinone derivative 118, respectively. We conclusively determined that compounds 100 and 118 suppressed the replication of influenza virus and exhibited anti-influenza virus activity against both influenza virus types A and B in the range of 50% effective concentration (EC50) = 0.061-0.226 μM with low toxicity (50% cytotoxic concentration (CC50) >10 μM).
Collapse
Affiliation(s)
- Satoshi Mizuta
- Center for Bioinformatics and Molecular Medicine, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo, Nagasaki 852-8521, Japan
| | - Hiroki Otaki
- Center for Bioinformatics and Molecular Medicine, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo, Nagasaki 852-8521, Japan
| | - Takeshi Ishikawa
- Department of Chemistry, Biotechnology, and Chemical Engineering, Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Korimoto, Kagoshima 890-0065, Japan
| | - Juliann Nzembi Makau
- Center for Virus Research, Kenya Medical Research Institute, 54840-00200 Nairobi, Kenya
| | - Tomoko Yamaguchi
- Center for Bioinformatics and Molecular Medicine, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo, Nagasaki 852-8521, Japan
| | - Takuya Fujimoto
- Chemistry, Discovery Science, Axcelead Drug Discovery Partners, Inc., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Nobuyuki Takakura
- Chemistry, Discovery Science, Axcelead Drug Discovery Partners, Inc., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Nobuki Sakauchi
- Chemistry, Discovery Science, Axcelead Drug Discovery Partners, Inc., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Shuji Kitamura
- Chemistry, Discovery Science, Axcelead Drug Discovery Partners, Inc., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
| | - Hikaru Nono
- School of Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
| | - Ryota Nishi
- School of Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
| | - Yoshimasa Tanaka
- Center for Medical Innovation, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8588, Japan
| | - Kohsuke Takeda
- Department of Cell Regulation, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo, Nagasaki 852-8521, Japan
| | - Noriyuki Nishida
- Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
| | - Ken Watanabe
- Department of Lifestyle Design, Faculty of Human Ecology, Yasuda Women's University, 6-13-1 Yasuhigashi, Asaminami Ward, Hiroshima 731-0153, Japan
| |
Collapse
|
9
|
Shibata S, Sogabe S, Miwa M, Fujimoto T, Takakura N, Naotsuka A, Kitamura S, Kawamoto T, Soga T. Identification of the first highly selective inhibitor of human lactate dehydrogenase B. Sci Rep 2021; 11:21353. [PMID: 34725423 PMCID: PMC8560939 DOI: 10.1038/s41598-021-00820-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Accepted: 10/18/2021] [Indexed: 02/04/2023] Open
Abstract
Lactate dehydrogenase (LDH) catalyses the conversion of pyruvate to lactate and NADH to NAD+; it has two isoforms, LDHA and LDHB. LDHA is a promising target for cancer therapy, whereas LDHB is necessary for basal autophagy and cancer cell proliferation in oxidative and glycolytic cancer cells. To the best of our knowledge, selective inhibitors for LDHB have not yet been reported. Here, we developed a high-throughput mass spectrometry screening system using an LDHB enzyme assay by detecting NADH and NAD+. As a result, we identified a small-molecule LDHB selective inhibitor AXKO-0046, an indole derivative. This compound exhibited uncompetitive LDHB inhibition (EC50 = 42 nM). X-ray crystallography revealed that AXKO-0046 bound to the potential allosteric site away from the LDHB catalytic active site, suggesting that targeting the tetramerisation interface of the two dimers is critical for the enzymatic activity. AXKO-0046 and its derivatives can be used to validate LDHB-associated pathways in cancer metabolism.
Collapse
Affiliation(s)
- Sachio Shibata
- Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan.
| | - Satoshi Sogabe
- Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan
| | - Masanori Miwa
- Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan
| | - Takuya Fujimoto
- Chemistry, Discovery Science, Axcelead Drug Discovery Partners, Inc., 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan
| | - Nobuyuki Takakura
- Chemistry, Discovery Science, Axcelead Drug Discovery Partners, Inc., 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan
| | - Akihiko Naotsuka
- Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan
| | - Shuji Kitamura
- Chemistry, Discovery Science, Axcelead Drug Discovery Partners, Inc., 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan
| | - Tomohiro Kawamoto
- Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Japan.
| | - Tomoyoshi Soga
- Institute for Advanced Biosciences, Keio University, 246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata, Japan
| |
Collapse
|
10
|
Takemori T, Kawamoto T, Morishita M, Hara H, Fukase N, Kawakami Y, Fujiwara S, Kitayama K, Yahiro S, Miyamoto T, Fujimoto T, Fujita I, Mifune Y, Hoshino Y, Kakutani K, Matsumoto T, Matsushita T, Niikura T, Kuroda R, Akisue T. Clinical Outcome of the Patients With Brain Metastasis from Soft Tissue Sarcomas. Anticancer Res 2021; 41:1027-1034. [PMID: 33517311 DOI: 10.21873/anticanres.14858] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Revised: 12/31/2020] [Accepted: 01/04/2021] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM This study aimed to evaluate the association of clinical characteristics with treatment outcomes to ascertain the appropriate treatment options for soft tissue sarcomas (STS) patients with brain metastasis (BM). PATIENTS AND METHODS Medical records of STS patients with BM who were treated in our institutions were retrospectively reviewed, and analyzed to identify the factors associated with post-BM survival. RESULTS Among the 509 STS patients, BM occurred in five patients (0.98%). The median survival after BM was 1.5 months. Histological subtypes of the primary lesions in the five BM patients were: two synovial sarcomas, one myxoid liposarcoma, one alveolar soft part sarcoma, and one rhabdomyosarcoma. Among the five BM patients, the post-BM survival of two patients, who underwent surgery and postoperative radiotherapy, was longer than that of the other patients (p<0.01). CONCLUSION Combined surgery and postoperative radiotherapy effectively managed symptoms and prolonged survival in STS patients with BM.
Collapse
Affiliation(s)
- Toshiyuki Takemori
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Teruya Kawamoto
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan; .,Division of Orthopaedic Surgery, Kobe University Hospital International Clinical Cancer Research Center, Kobe, Japan
| | | | - Hitomi Hara
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Naomasa Fukase
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yohei Kawakami
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Shuichi Fujiwara
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Kazumichi Kitayama
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Shunsuke Yahiro
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tomohiro Miyamoto
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Takuya Fujimoto
- Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi, Japan
| | - Ikuo Fujita
- Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi, Japan
| | - Yutaka Mifune
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yuichi Hoshino
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Kenichiro Kakutani
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tomoyuki Matsumoto
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Takehiko Matsushita
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Takahiro Niikura
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Ryosuke Kuroda
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Toshihiro Akisue
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.,Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan
| |
Collapse
|
11
|
Endo T, Fujimoto T, Nishioka S, Yokoyama N, Ogawa S, Ishimura T, Fujisawa M. Influence of everolimus on mycophenolate mofetil pharmacokinetics in kidney transplant patients. Korean Journal of Transplantation 2020. [DOI: 10.4285/atw2020.po-1062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Affiliation(s)
- Takahito Endo
- Department of Urology, Kobe University Hospital, Kobe, Japan
| | - Takuya Fujimoto
- Department of Urology, Kobe University Hospital, Kobe, Japan
| | - Shun Nishioka
- Department of Urology, Kobe University Hospital, Kobe, Japan
| | - Naoki Yokoyama
- Department of Urology, Kobe University Hospital, Kobe, Japan
| | - Satoshi Ogawa
- Department of Urology, Kobe University Hospital, Kobe, Japan
| | | | - Masato Fujisawa
- Department of Urology, Kobe University Hospital, Kobe, Japan
| |
Collapse
|
12
|
Fujimoto T, Tsunedomi R, Matsukuma S, Yoshimura K, Oga A, Fujiwara N, Fujiwara Y, Matsui H, Shindo Y, Tokumitsu Y, Suzuki N, Kobayashi S, Hazama S, Eguchi H, Nagano H. Cathepsin B is highly expressed in pancreatic cancer stem-like cells and is associated with patients' surgical outcomes. Oncol Lett 2020; 21:30. [PMID: 33240436 PMCID: PMC7681200 DOI: 10.3892/ol.2020.12291] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Accepted: 09/15/2020] [Indexed: 12/12/2022] Open
Abstract
Cancer stem-like cells (CSLCs) in solid tumors are resistant to conventional chemotherapy and molecularly targeted therapy, which is thought to contribute to cancer recurrence and metastasis. The present study aimed to identify biomarkers for pancreatic CSLCs (P-CSLCs). Using our previously reported methods, P-CSLC-enriched populations were generated from pancreatic cancer cell lines. The protein expression profiles of these populations were compared with those of parental cells using two-dimensional electrophoresis, tandem mass spectrometry, flow cytometry and immunohistochemistry. Protein expression in surgical specimens was also evaluated for relationships with clinical outcomes. A lysosomal cysteine protease, cathepsin B (CTSB), was significantly upregulated in P-CSLCs compared with that in the parental cells, as shown using western blotting. Flow cytometry analysis also confirmed that CTSB was more highly expressed on the surface of P-CSLCs compared with that on parental cells. Moreover, PCLCs had elevated cellular secretions of CTSB compared with the parental cells. Finally, CTSB expression was evaluated in 69 resected tumor specimens, and high expression was associated with the patients' clinicopathological features and surgical outcomes. The present results suggested that CTSB is a biomarker for poor survival in patients with pancreatic cancer, which is possibly associated with P-CSLCs. This novel biomarker may also have potential as a therapeutic target.
Collapse
Affiliation(s)
- Takuya Fujimoto
- Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan
| | - Ryouichi Tsunedomi
- Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan
| | - Satoshi Matsukuma
- Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan
| | - Kiyoshi Yoshimura
- Department of Clinical Research in Tumor Immunology, Showa University Clinical Research Institute for Clinical Pharmacology and Therapeutics, Setagaya, Tokyo 157-8577, Japan
| | - Atsunori Oga
- Department of Molecular Pathology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan
| | - Nobuyuki Fujiwara
- Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan
| | - Yasuhiro Fujiwara
- Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan
| | - Hiroto Matsui
- Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan
| | - Yoshitaro Shindo
- Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan
| | - Yukio Tokumitsu
- Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan
| | - Nobuaki Suzuki
- Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan
| | - Shogo Kobayashi
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
| | - Shoichi Hazama
- Department of Translational Research and Developmental Therapeutics Against Cancer, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan
| | - Hidetoshi Eguchi
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
| | - Hiroaki Nagano
- Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan
| |
Collapse
|
13
|
Andoh T, Fujimoto T, Satani R, Suzuki M, Wada K, Sudo T, Sakurai Y, Tanaka H, Takata T, Ichikawa H. Preclinical study of boron neutron capture therapy for bone metastasis using human breast cancer cell lines. Appl Radiat Isot 2020; 165:109257. [PMID: 32777739 DOI: 10.1016/j.apradiso.2020.109257] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2019] [Revised: 05/01/2020] [Accepted: 05/31/2020] [Indexed: 11/29/2022]
Abstract
Bone metastasis has a major impact on the quality of life that general therapy cannot control. We established a bone metastasis model with a human breast cancer cell line and investigated the therapeutic effect of boron neutron capture therapy (BNCT). BNCT suppressed tumor growth in cases of intramedullary small tumors without damaging normal tissues, providing preliminary evidence that it is a potentially new therapeutic option for controlling tumor growth from bone metastasis. Further research is warranted for its clinical application.
Collapse
Affiliation(s)
- Tooru Andoh
- Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, 650-8586, Japan.
| | - Takuya Fujimoto
- Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi, 673-8558, Japan
| | - Ryoichi Satani
- Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, 650-8586, Japan
| | - Minoru Suzuki
- Particle Radiation Oncology, Institute for Integrated Radiation and Nuclear Science, Kyoto University, Sennan-gun, 590-0494, Japan
| | - Keijiro Wada
- Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, 650-8586, Japan
| | - Tamotsu Sudo
- Section of Translational Research, Hyogo Cancer Center, Akashi, 673-8558, Japan
| | - Yoshinori Sakurai
- Particle Radiation Medical Physics, Institute for Integrated Radiation and Nuclear Science, Kyoto University, Sennan-gun, 590-0494, Japan
| | - Hiroki Tanaka
- Particle Radiation Medical Physics, Institute for Integrated Radiation and Nuclear Science, Kyoto University, Sennan-gun, 590-0494, Japan
| | - Takushi Takata
- Particle Radiation Medical Physics, Institute for Integrated Radiation and Nuclear Science, Kyoto University, Sennan-gun, 590-0494, Japan
| | - Hideki Ichikawa
- Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, 650-8586, Japan
| |
Collapse
|
14
|
Fujimoto T, Suzuki M, Sudo T, Fujita I, Sakuma T, Sakurai Y, Hirose T, Morishita M, Takata T, Tamari Y, Tanaka H, Andoh T, Kawamoto T, Hara H, Fukase N, Kawakami Y, Shigemoto R, Matsumoto T, Ichikawa H, Ono K, Kuroda R, Akisue T. Boron neutron capture therapy for clear cell sarcoma. Appl Radiat Isot 2020; 166:109324. [PMID: 32861973 DOI: 10.1016/j.apradiso.2020.109324] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Revised: 10/05/2019] [Accepted: 07/03/2020] [Indexed: 11/26/2022]
Abstract
Clear cell sarcoma of tendons and aponeuroses (CCS) is a rare, malignant tumor arising in lower extremities with no effective treatment other than wide surgical resection. Here described is a case of primary CCS in the peroneal tendon of the right foot of a 54-year-old woman enrolled to undergo BNCT. The tumor mass post-BNCT disappeared totally without damage to other normal tissue, demonstrating, for the first time, the potential efficacy of BNCT in complete local control of CCS.
Collapse
Affiliation(s)
- Takuya Fujimoto
- Department of Orthopaedic Surgery, Hyogo Cancer Center, 13-70 Kitaouji-cho, Akashi, 673-8558, Japan; Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, 590-0494, Japan
| | - Tamotsu Sudo
- Section of Translational Research, Hyogo Cancer Center, 13-70 Kitaouji-cho, Akashi, 673-8558, Japan
| | - Ikuo Fujita
- Department of Orthopaedic Surgery, Hyogo Cancer Center, 13-70 Kitaouji-cho, Akashi, 673-8558, Japan
| | - Toshiko Sakuma
- Department of Diagnostic Pathology, Hyogo Cancer Center, 13-70 Kitaouji-cho, Akashi, 673-8558, Japan
| | - Yoshinori Sakurai
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, 590-0494, Japan
| | - Takanori Hirose
- Department of Diagnostic Pathology, Hyogo Cancer Center, 13-70 Kitaouji-cho, Akashi, 673-8558, Japan
| | - Masayuki Morishita
- Department of Orthopaedic Surgery, Hyogo Cancer Center, 13-70 Kitaouji-cho, Akashi, 673-8558, Japan
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, 590-0494, Japan
| | - Yuki Tamari
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, 590-0494, Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, 590-0494, Japan
| | - Tooru Andoh
- Faculty of Pharmaceutical Sciences, Kobe Gakuin University, 1-1-3 Minatojima, Chuo-ku, Kobe, 650-8586, Japan
| | - Teruya Kawamoto
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan; Division of Orthopaedic Surgery, Kobe University International Clinical Cancer Research Center, 1-5-1 Minatojimaminami-cho, Chuo-ku, Kobe, 650-0047, Japan
| | - Hitomi Hara
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Naomasa Fukase
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Yohei Kawakami
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Rika Shigemoto
- Department of Orthopaedic Surgery, Hyogo Cancer Center, 13-70 Kitaouji-cho, Akashi, 673-8558, Japan
| | - Tomoyuki Matsumoto
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Hideki Ichikawa
- Faculty of Pharmaceutical Sciences, Kobe Gakuin University, 1-1-3 Minatojima, Chuo-ku, Kobe, 650-8586, Japan
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, 569-8686, Japan
| | - Ryosuke Kuroda
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Toshihiro Akisue
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan; Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, 7-10- 2 Tomogaoka, Suma-ku, Kobe, 654-0142, Japan
| |
Collapse
|
15
|
TAKAMURA T, Fujimoto T, Matsumoto N, Saito Y, Tajiri S, Yamanaka S, Matsumoto K, Okano james H, Yokoo T. SUN-313 A NEW NEPHRON PROGENITOR CELL REPLACEMENT SYSTEM CAN REGENERATE NEPHRONS FROM HUMAN INDUCED PLURIPOTENT STEM CELLS. Kidney Int Rep 2020. [DOI: 10.1016/j.ekir.2020.02.850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
16
|
Takagahara S, Shinohara H, Itokawa S, Satomi Y, Ando A, Yamamoto T, Suzuki H, Fujimoto T, Kubo K, Ikeda S. A Novel Orally Available Delta-5 Desaturase Inhibitor Prevents Atherosclerotic Lesions Accompanied by Changes in Fatty Acid Composition and Eicosanoid Production in ApoE Knockout Mice. J Pharmacol Exp Ther 2019; 371:290-298. [PMID: 31488602 DOI: 10.1124/jpet.119.259846] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Accepted: 08/30/2019] [Indexed: 01/12/2023] Open
Abstract
Delta-5 desaturase (D5D), encoded by fatty acid desaturase 1 (Fads1), is the rate-limiting enzyme for the conversion from dihomo-γ-linolenic acid (DGLA) to arachidonic acid (AA) in the ω-6 polyunsaturated fatty acid pathway. Several AA-derived eicosanoids (e.g., prostaglandins, thromboxanes, and leukotrienes) and DGLA-derived eicosanoids are reported to promote and/or prevent atherosclerosis progression through, at least in part, its proinflammatory or anti-inflammatory effects. To elucidate the effects of D5D inhibition by a D5D inhibitor on atherosclerosis, we generated a potent, orally available and selective D5D inhibitor, 2-(2,2,3,3,3-Pentafluoropropoxy)-3-[4-(2,2,2-trifluoroethoxy) phenyl]-5,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-4,6-dione, compound-326, and examined its effects on Western-diet fed ApoE knockout (KO) mice. Oral administration of compound-326 (3-10 mg/kg per day for 15 weeks) significantly inhibited the progression of atherosclerotic lesions in the aorta without affecting plasma total cholesterol and triglyceride levels. Compound-326 significantly decreased AA levels, while it increased DGLA levels in the liver and the blood accompanied by decreases in AA-derived eicosanoid production and increases in DGLA-derived eicosanoid production from the blood cells. We conclude that compound-326 prevents the progression of atherosclerosis in Western-diet fed ApoE KO mice by modulating a profile of eicosanoid production, suggesting that D5D inhibitors can be a novel remedy for preventing atherosclerosis and subsequent cardiovascular events. SIGNIFICANCE STATEMENT: This study shows a D5D-specific and orally available potent inhibitor provided the first evidence to support the concept that D5D inhibitors will be a novel remedy for preventing the progression of atherosclerosis.
Collapse
Affiliation(s)
- Shuichi Takagahara
- Cardiovascular and Metabolic Drug Discovery Unit (S.T., H.Sh, S.I., T.Y., H.Su, T.F., K.K., S.I.) and Integrated Technology Research Laboratories (Y.S., A.A.), Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Hiromi Shinohara
- Cardiovascular and Metabolic Drug Discovery Unit (S.T., H.Sh, S.I., T.Y., H.Su, T.F., K.K., S.I.) and Integrated Technology Research Laboratories (Y.S., A.A.), Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Shigekazu Itokawa
- Cardiovascular and Metabolic Drug Discovery Unit (S.T., H.Sh, S.I., T.Y., H.Su, T.F., K.K., S.I.) and Integrated Technology Research Laboratories (Y.S., A.A.), Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Yoshinori Satomi
- Cardiovascular and Metabolic Drug Discovery Unit (S.T., H.Sh, S.I., T.Y., H.Su, T.F., K.K., S.I.) and Integrated Technology Research Laboratories (Y.S., A.A.), Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Ayumi Ando
- Cardiovascular and Metabolic Drug Discovery Unit (S.T., H.Sh, S.I., T.Y., H.Su, T.F., K.K., S.I.) and Integrated Technology Research Laboratories (Y.S., A.A.), Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Takeshi Yamamoto
- Cardiovascular and Metabolic Drug Discovery Unit (S.T., H.Sh, S.I., T.Y., H.Su, T.F., K.K., S.I.) and Integrated Technology Research Laboratories (Y.S., A.A.), Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Hideo Suzuki
- Cardiovascular and Metabolic Drug Discovery Unit (S.T., H.Sh, S.I., T.Y., H.Su, T.F., K.K., S.I.) and Integrated Technology Research Laboratories (Y.S., A.A.), Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Takuya Fujimoto
- Cardiovascular and Metabolic Drug Discovery Unit (S.T., H.Sh, S.I., T.Y., H.Su, T.F., K.K., S.I.) and Integrated Technology Research Laboratories (Y.S., A.A.), Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Kazuki Kubo
- Cardiovascular and Metabolic Drug Discovery Unit (S.T., H.Sh, S.I., T.Y., H.Su, T.F., K.K., S.I.) and Integrated Technology Research Laboratories (Y.S., A.A.), Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| | - Shota Ikeda
- Cardiovascular and Metabolic Drug Discovery Unit (S.T., H.Sh, S.I., T.Y., H.Su, T.F., K.K., S.I.) and Integrated Technology Research Laboratories (Y.S., A.A.), Takeda Pharmaceutical Company Limited, Kanagawa, Japan
| |
Collapse
|
17
|
Nambu K, Koma Y, Sakata H, Kyuma H, Sugimoto K, Fujimoto T. Clinical study of 31 cases of dental implants with maxillary sinus floor augmentation. Int J Oral Maxillofac Surg 2019. [DOI: 10.1016/j.ijom.2019.03.639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
18
|
Nakamura M, Namiki T, Munetsugu T, Hashimoto T, Fujimoto T, Yokozeki H. Image Gallery: Acquired anhidrosis associated with alcohol-related peripheral neuropathy, a potential cause of anhidrosis due to reduced innervation of eccrine glands. Br J Dermatol 2019; 180:e35. [PMID: 30714116 DOI: 10.1111/bjd.17247] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- M Nakamura
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - T Namiki
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - T Munetsugu
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - T Hashimoto
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - T Fujimoto
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - H Yokozeki
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| |
Collapse
|
19
|
Kubota H, Soejima T, Sulaiman NS, Sekii S, Matsumoto Y, Ota Y, Tsujino K, Fujita I, Fujimoto T, Morishita M, Ikegaki J, Matsumoto K, Sasaki R. Predicting the survival of patients with bone metastases treated with radiation therapy: a validation study of the Katagiri scoring system. Radiat Oncol 2019; 14:13. [PMID: 30658673 PMCID: PMC6339356 DOI: 10.1186/s13014-019-1218-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Accepted: 01/09/2019] [Indexed: 12/26/2022] Open
Abstract
Background The selection of radiation therapy dose fractionation schedules for bone metastases is often based on the estimation of life expectancy. Therefore, accurate prognosis prediction is an important issue. It is reported that the Katagiri scoring system can be used to predict the survival of patients with bone metastases. We aimed to assess prognostic factors and validate the Katagiri scoring system in patients who were treated with radiation therapy for bone metastases. Materials/Methods We retrospectively reviewed data of all patients who were treated with radiation therapy for bone metastases between 2004 and 2013. Age, sex, Karnofsky performance status (KPS), Eastern Cooperative Oncology Group performance status (ECOG PS), primary site (lesions and characteristics), visceral metastases, laboratory data, previous chemotherapy, and multiple bone metastases were analyzed for associations with overall survival (OS). Katagiri scores were calculated for each patient and were used to compare OS. Results Out of the 616 patients included in this analysis, 574 had died and 42 remained alive. The median follow-up time for survivors was 42 months. Univariate analysis revealed that age (P = 0.604) and multiple bone metastases (P = 0.691) were not significantly associated with OS. Multivariate analysis revealed that sex, ECOG PS, KPS, primary characteristics, visceral metastases, laboratory data, and previous chemotherapy were significantly associated with OS. The survival rates at 3, 6, 12, and 24 months, categorized by Katagiri score, were as follows: score 0–3, 94.4, 77.8, and 61.1%, respectively; score 4–6, 67.7, 48.7, and 31.2%, respectively; and score 7–10, 39.1, 22.1, and 9.0%, respectively (P < 0.001). Conclusion Sex, ECOG PS, KPS, primary characteristics, visceral metastases, laboratory data, and previous chemotherapy were significant predictors of survival in patients with bone metastases. The Katagiri scoring system was significantly correlated with OS and can help us select the optimal dose-fractionation. Electronic supplementary material The online version of this article (10.1186/s13014-019-1218-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Hikaru Kubota
- Department of Radiation Oncology, Hyogo Cancer Center, 13-70, Kita-oji, Akashi, Hyogo, Japan. .,Department of Radiation Oncology, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, Japan.
| | - Toshinori Soejima
- Department of Radiation Oncology, Hyogo Cancer Center, 13-70, Kita-oji, Akashi, Hyogo, Japan.,Department of Radiation Oncology, Kobe Proton Center, 1-6-8, Minatojima-minami-cho, Chuo-ku, Kobe, Japan
| | - Nor Shazrina Sulaiman
- Department of Radiation Oncology, Hyogo Cancer Center, 13-70, Kita-oji, Akashi, Hyogo, Japan
| | - Shuhei Sekii
- Department of Radiation Oncology, Hyogo Cancer Center, 13-70, Kita-oji, Akashi, Hyogo, Japan
| | - Yoko Matsumoto
- Department of Radiation Oncology, Hyogo Cancer Center, 13-70, Kita-oji, Akashi, Hyogo, Japan
| | - Yosuke Ota
- Department of Radiation Oncology, Hyogo Cancer Center, 13-70, Kita-oji, Akashi, Hyogo, Japan
| | - Kayoko Tsujino
- Department of Radiation Oncology, Hyogo Cancer Center, 13-70, Kita-oji, Akashi, Hyogo, Japan
| | - Ikuo Fujita
- Department of Orthopaedic Surgery, Hyogo Cancer Center, 13-70, Kita-oji, Akashi, Hyogo, Japan
| | - Takuya Fujimoto
- Department of Orthopaedic Surgery, Hyogo Cancer Center, 13-70, Kita-oji, Akashi, Hyogo, Japan
| | - Masayuki Morishita
- Department of Orthopaedic Surgery, Hyogo Cancer Center, 13-70, Kita-oji, Akashi, Hyogo, Japan
| | - Junichi Ikegaki
- Department of Palliative Medicine, Hyogo Cancer Center, 13-70, Kita-oji, Akashi, Hyogo, Japan
| | - Koji Matsumoto
- Department of Medical Oncology, Hyogo Cancer Center, 13-70, Kita-oji, Akashi, Hyogo, Japan
| | - Ryohei Sasaki
- Department of Radiation Oncology, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, Japan
| |
Collapse
|
20
|
Fujimoto T, Kaneko T, Sunakawa T, Ikegami H, Musha Y. Elevation of fibrin degradation product (FDP) values prevents the negative conversion of serum CRP values after total knee arthroplasty. J Orthop 2018; 15:940-944. [PMID: 30202143 DOI: 10.1016/j.jor.2018.08.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Accepted: 08/02/2018] [Indexed: 11/19/2022] Open
Abstract
Background It is essential as an orthopedic surgeon to diagnose prosthetic joint infection (PJI) at an early stage and to carry out precise treatment as well as preventing the deterioration of functional prognosis as much as possible. We suspected that PJI might have been caused because the negative conversion of creatinine reactive protein (CRP) has been prolonged after total knee arthroplasty (TKA) and patients with no serum CRP negative conversion have been treated with antibiotics to avoid the morbidity of PJI. The purpose of the present study is to investigate the factors associated with prolongation of the negative conversion of CRP, with the exclusion of PJI patients. Methods We performed a retrospective case control study at our institution from August 2014 to August 2016. We classified the patients into two groups based on whether it required ≥20 days (Group A, n = 23) or <20 days (Group B, n = 23) for CRP levels to normalize. Serum D-Dimer and fibrin degradation product (FDP) values were measured at 1, 2, 5, 9, 12, 16, 19, 23, 26, and 30 days after TKA. Exclusion criteria include anticoagulant oral administration cases before TKA, venous thromboembolism (VTE) by postoperative lower limb venous echocardiography before and after TKA, CRP re-elevation cases, and patients with PJI. The cutoff points for D-dimer and FDP levels for screening tests were calculated from the receiver operating characteristic (ROC) curve. Results The ROC analysis of D- Dimer values at 30 days after TKA yielded an AUC of 0.891 (95% confidence interval (CI) 0.858-1.000), which indicates nearly an excellent test. The cutoff point of 22.1 μg/dl for FDP value (Younden Index: 22.1 μg/dl) showed a sensitivity of 81.8% (95% CI 70.1-92.8) and a specificity of 80.0% (95% CI 67.9-89.1). Conclusion We revealed that CRP values of patient with an FDP level ≥22.1 μg/dl at 30 days after TKA necessarily showed negative conversion without antibiotic administration, when examining a patient with elevated serum CRP of minor criteria in the definition of PJI proposed by MSIS (other criteria do not apply). Level of evidence Ⅲ.
Collapse
Affiliation(s)
- Takuya Fujimoto
- Department of Orthopedic Surgery, Toho University School of Medicine, 2-17-6 Ohashi, Meguro-ku, Tokyo, 153-8515, Japan
| | - Takao Kaneko
- Department of Orthopedic Surgery, Toho University School of Medicine, 2-17-6 Ohashi, Meguro-ku, Tokyo, 153-8515, Japan
| | - Takahide Sunakawa
- Department of Orthopedic Surgery, Toho University School of Medicine, 2-17-6 Ohashi, Meguro-ku, Tokyo, 153-8515, Japan
| | - Hiroyasu Ikegami
- Department of Orthopedic Surgery, Toho University School of Medicine, 2-17-6 Ohashi, Meguro-ku, Tokyo, 153-8515, Japan
| | - Yoshiro Musha
- Department of Orthopedic Surgery, Toho University School of Medicine, 2-17-6 Ohashi, Meguro-ku, Tokyo, 153-8515, Japan
| |
Collapse
|
21
|
Ueki H, Fujimoto T, Okuno M, Kusuda Y, Taguchi I, Itou Y, Kiyonaka S, Kawabata G. The Use of CT-Guided Marking for the Laparoscopic Resection of a Solitary Retroperitoneal Metastasis of Colon Cancer. J Endourol Case Rep 2018; 4:120-123. [PMID: 30087907 PMCID: PMC6080126 DOI: 10.1089/cren.2018.0049] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background: CT-guided marking technique is rarely used in abdominal or urologic surgery. We developed and performed a marking technique for a small tumor, undetectable by ultrasound, using CT guidance before laparoscopic resection of the tumor. Case Presentation: A 73-year-old woman with a history of breast cancer underwent right colectomy with D3 lymph node dissection for ascending colon cancer. Five years after the operation, a solitary tumor was found in the right pararenal region of the retroperitoneal space on enhanced abdominal CT. The tumor was 20 mm in diameter and undetectable by ultrasound, so we performed a marking technique using CT guidance before the operation. Placing the patient in a prone position on the CT table, a 22-gauge needle was inserted into the Gerota's fascia percutaneously and a mixed fluid containing India ink and Iopamidol was injected para to the tumor by the radiologist. During the surgery, the marker was clearly identified and the cutting line was determined to ensure a sufficient surgical margin. The tumor was laparoscopically resected as planned. The histopathologic diagnosis was adenocarcinoma, compatible with metastasis of colon cancer. The postoperative course was uneventful and the patient remained free of disease at 10 months after surgery. Conclusion: When resecting small tumors or tumors with an irregular margin, a marking technique is conducted before the surgery. But, preoperative CT-guided marking has not been applied generally for resection of intraabdominal lesion yet. CT-guided marking can be effective when performing minimally invasive and curable surgery on small tumors. This is the first report of an effective CT-guided marking before retroperitoneal laparoscopic tumorectomy. We believe that this technique provides an important therapeutic option for small tumors that may be undetectable by ultrasound.
Collapse
Affiliation(s)
- Hideto Ueki
- Division of Urology, Kansai Rosai Hospital, Amagasaki, Japan
| | - Takuya Fujimoto
- Division of Urology, Kansai Rosai Hospital, Amagasaki, Japan
| | - Masato Okuno
- Division of Urology, Kansai Rosai Hospital, Amagasaki, Japan
| | - Yuji Kusuda
- Division of Urology, Kansai Rosai Hospital, Amagasaki, Japan
| | - Isao Taguchi
- Division of Urology, Kansai Rosai Hospital, Amagasaki, Japan
| | - Yasushi Itou
- Division of Radiology, Kansai Rosai Hospital, Amagasaki, Japan
| | - Sawami Kiyonaka
- Division of Anesthesia, Kansai Rosai Hospital, Amagasaki, Japan
| | - Gaku Kawabata
- Division of Urology, Kansai Rosai Hospital, Amagasaki, Japan
| |
Collapse
|
22
|
Yukitake H, Ishikawa T, Suzuki A, Shimizu Y, Nakashima M, Fujimoto T, Rikimaru K, Ito M, Suzuki M, Kimura H. 0002 An Orexin 2 Receptor-selective Agonist, TAK-925, Shows Robust Wake-promoting Effects In Mice And Non-human Primates. Sleep 2018. [DOI: 10.1093/sleep/zsy061.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- H Yukitake
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, JAPAN
| | - T Ishikawa
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, JAPAN
| | - A Suzuki
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, JAPAN
| | - Y Shimizu
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, JAPAN
| | - M Nakashima
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, JAPAN
| | - T Fujimoto
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, JAPAN
| | - K Rikimaru
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, JAPAN
| | - M Ito
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, JAPAN
| | - M Suzuki
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, JAPAN
| | - H Kimura
- Research, Takeda Pharmaceutical Company Limited, Fujisawa, JAPAN
| |
Collapse
|
23
|
Abstract
In a previous communication, we reported a leaflet fracture in a Jellyfish valve that was incorporated into a blood pump, after a 312-day animal implant duration. Subsequent finite element analysis revealed that the fracture location was consistent with an area of maximum strain concentration. Therefore, the aim of this study was to improve the durability in the light of these findings. Based on the engineering analysis results, a new valve seat having a concentric ring of 0.5mm width, located at a radius of 7.0 mm, was designed and fabricated. Accelerated fatigue tests, conducted under the conditions recommended by ISO 5840, demonstrated that the durability of this new prototype was extended by a factor of 10, as compared to the original valve. Moreover, further finite element analysis indicated that the maximum equivalent elastic strain of the proposed new valve was reduced by 52.3% as compared to the original valve. Accordingly, it has been confirmed that the modified Jellyfish valve is suitable for use in long-term artificial hearts.
Collapse
Affiliation(s)
- K. Iwasaki
- Department of Mechanical Engineering, Waseda University, Tokyo - Japan
| | - M. Umezu
- Department of Mechanical Engineering, Waseda University, Tokyo - Japan
| | - K. Imachi
- Department of Biomedical Engineering, Graduate School of Medicine, The University of Tokyo, Tokyo - Japan
| | - K. Iijima
- Department of Mechanical Engineering, Waseda University, Tokyo - Japan
| | - T. Fujimoto
- Department of Mechanical Engineering, Shibaura Institute of Technology, Tokyo - Japan
| |
Collapse
|
24
|
Yamanaka S, Tajiri S, Fujimoto T, Matsumoto K, Fukunaga S, Kim BS, Okano HJ, Yokoo T. Generation of interspecies limited chimeric nephrons using a conditional nephron progenitor cell replacement system. Nat Commun 2017; 8:1719. [PMID: 29170512 PMCID: PMC5701015 DOI: 10.1038/s41467-017-01922-5] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Accepted: 10/25/2017] [Indexed: 01/08/2023] Open
Abstract
Animal fetuses and embryos may have applications in the generation of human organs. Progenitor cells may be an appropriate cell source for regenerative organs because of their safety and availability. However, regenerative organs derived from exogenous lineage progenitors in developing animal fetuses have not yet been obtained. Here, we established a combination system through which donor cells could be precisely injected into the nephrogenic zone and native nephron progenitor cells (NPCs) could be eliminated in a time- and tissue-specific manner. We successfully achieved removal of Six2+ NPCs within the nephrogenic niche and complete replacement of transplanted NPCs with donor cells. These NPCs developed into mature glomeruli and renal tubules, and blood flow was observed following transplantation in vivo. Furthermore, this artificial nephron could be obtained using NPCs from different species. Thus, this technique enables in vivo differentiation from progenitor cells into nephrons, providing insights into nephrogenesis and organ regeneration. The transplantation of tissue-specific progenitor cells may be an approach in organ regeneration. Here the authors show that the nephron progenitor population of a developing mouse kidney, when ablated, can be replaced by exogenously supplied rat nephron progenitors, generating interspecies nephrons.
Collapse
Affiliation(s)
- S Yamanaka
- Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, 1058461, Japan
| | - S Tajiri
- Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, 1058461, Japan.,Division of Regenerative Medicine, Jikei University School of Medicine, Tokyo, 1058461, Japan
| | - T Fujimoto
- Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, 1058461, Japan.,Division of Regenerative Medicine, Jikei University School of Medicine, Tokyo, 1058461, Japan
| | - K Matsumoto
- Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, 1058461, Japan
| | - S Fukunaga
- Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, 1058461, Japan.,Department of Internal Medicine IV, Shimane University, Izumo, Shimane, 6938501, Japan
| | - B S Kim
- Division of Regenerative Medicine, Jikei University School of Medicine, Tokyo, 1058461, Japan.,Department of Urology, Kyungpook National University School of Medicine, Daegu, 41944, Korea
| | - H J Okano
- Division of Regenerative Medicine, Jikei University School of Medicine, Tokyo, 1058461, Japan
| | - T Yokoo
- Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, 1058461, Japan.
| |
Collapse
|
25
|
Fujimoto T, Suzuki N, Tomochika S, Tanaka H, Matsui H, Sakamoto K, Takeda S, Yamamoto S, Yoshino S, Hazama S, Ishibashi H, Yonemura Y, Ueno T, Nagano H. [A Case of Colorectal Cancer with Peritoneal Dissemination and Liver Metastasis That Responded to Comprehensive Treatment by Chemotherapy and CRS plus HIPEC]. Gan To Kagaku Ryoho 2017; 44:1704-1707. [PMID: 29394749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
We report a case of colorectal cancer with peritoneal dissemination and liver metastasis that achieved R0 resection by preoperative chemotherapy and CRS plus HIPEC. A 33-year-old man presented with a complaint of abdominal bloating. After further examination, he was diagnosed with transverse colon cancer with peritoneal dissemination and liver metastasis. After 9 courses of preoperative XELOX plus cetuximab and 4 courses of preoperative XELIRI plus bevacizumab, he underwent transverse colon resection, peritoneal resection, and HIPEC(MMC 20mg/4,000mL physiological saline, 40mins). There was little histological evidence of peritoneal dissemination around the region of the primary tumor. Moreover, no tumor cells were found in other peritoneal disseminations or in the liver metastasis. As a result, he was able to undergo curative resection. Colorectal cancer with peritoneal dissemination still has a poor prognosis, but combination therapy with chemotherapy and CRS plus HIPEC is expected to improve prognosis.
Collapse
Affiliation(s)
- Takuya Fujimoto
- Dept. of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School Medicine
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Fujimoto T, Ichinose M, Fukumoto S, Mizota T. Evaluations of serum anti-ganglioside antibody, initial symptoms and effectiveness of immunoglobulin therapy in patients with Guillain-Barre syndrome. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Koide M, Matsuo A, Fukui K, Fujimoto T, Shimoo S, Takamatsu K, Kyodo A, Irie D, Tsubakimoto Y, Isodono K, Sakatani T, Inoue K, Fujita H. P3353Cholesterol crystal depth in coronary atherosclerotic plaques: a novel index of plaque vulnerability using optical frequency domain imaging. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p3353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
28
|
Sugimoto K, Isaka M, Fujimoto T, Akasaka H, Yamamoto K, Rakugi H. THE USEFULNESS OF LOWER-LIMB MUSCLE ULTRASONOGRAPHY AS A DIAGNOSTIC METHOD OF SARCOPENIA. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.1426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- K. Sugimoto
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - M. Isaka
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - T. Fujimoto
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - H. Akasaka
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - K. Yamamoto
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - H. Rakugi
- Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| |
Collapse
|
29
|
Tanaka T, Suzuki S, Nishino I, Hamaguchi Y, Fujimoto T. What is the third serological marker associated with immune-mediated necrotizing myopathy? Scand J Rheumatol 2017; 46:416-417. [PMID: 28067601 DOI: 10.1080/03009742.2016.1258730] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- T Tanaka
- a Department of General Internal Medicine, Tazuke-Kofukai, Medical Research Institute , Kitano Hospital , Osaka , Japan
| | - S Suzuki
- b Department of Neurology , Keio University School of Medicine , Tokyo , Japan
| | - I Nishino
- c National Center of Neurology and Psychiatry , Kodaira , Japan
| | - Y Hamaguchi
- d Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences , Kanazawa University , Ishikawa , Japan
| | - T Fujimoto
- a Department of General Internal Medicine, Tazuke-Kofukai, Medical Research Institute , Kitano Hospital , Osaka , Japan
| |
Collapse
|
30
|
Azuma T, Kumagai T, Sato T, Mashio G, Fujimoto T, Akiyama S, Yokohara H, Hoshino T, Miyake T. Evaluation of machinable lithium disilicate glass ceramic block for CAD/CAM. Dent Mater 2017. [DOI: 10.1016/j.dental.2017.08.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
31
|
Mayahara H, Ando T, Fujimoto T, Ogawa K. Membrane Na/K-Adenosine Triphosphatase (ATPase) (K-P-Nitrophenylphosphate) in Epithelial Cells. J Histochem Cytochem 2016; 31:224-226. [DOI: 10.1177/31.1a_suppl.6298306] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- H. Mayahara
- Central Research Laboratories (H.M.: T.A.). Takeda Chemical Industries, Osaka 569, Japan, and Department of Anatomy (T.F.; K.O.), Faculty of Medicine, Kyoto University, Kyoto 606, Japan (OA 82-283P2)
| | - T. Ando
- Central Research Laboratories (H.M.: T.A.). Takeda Chemical Industries, Osaka 569, Japan, and Department of Anatomy (T.F.; K.O.), Faculty of Medicine, Kyoto University, Kyoto 606, Japan (OA 82-283P2)
| | - T. Fujimoto
- Central Research Laboratories (H.M.: T.A.). Takeda Chemical Industries, Osaka 569, Japan, and Department of Anatomy (T.F.; K.O.), Faculty of Medicine, Kyoto University, Kyoto 606, Japan (OA 82-283P2)
| | - K. Ogawa
- Central Research Laboratories (H.M.: T.A.). Takeda Chemical Industries, Osaka 569, Japan, and Department of Anatomy (T.F.; K.O.), Faculty of Medicine, Kyoto University, Kyoto 606, Japan (OA 82-283P2)
| |
Collapse
|
32
|
Fujimoto T, Ueno T, Sakamoto K, Matsukuma S, Matsui H, Shindo Y, Tokumitsu Y, Kanekiyo S, Iida M, Tokuhisa Y, Suzuki N, Takeda S, Yoshino S, Hazama S, Nagano H. [A Case of Borderline Resectable Pancreatic Cancer Responding to Preoperative GEM plus Nab-PTX Combination Chemotherapy]. Gan To Kagaku Ryoho 2016; 43:1978-1981. [PMID: 28133195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
We report a case of borderline resectable(BR)pancreatic cancer, which was eligible for R0 resection following preoperative chemotherapy with GEM plus nab-PTX. A 77-year-old woman presented with brown urine and clay-colored stool. After further examination, she was diagnosed with obstructive jaundice due to pancreatic head cancer. Because the tumor was in contact with the region attached to the SMA nerve plexus, she was also diagnosed with BR-A pancreatic cancer. After 6 courses of preoperative GEM plus nab-PTX combination chemotherapy, she underwent subtotal stomach-preservingpancreaticoduodenectomy with SMV resection and right semicircular SMA nerve plexus dissection. In the histopathological diagnosis, malignant cells were observed at low levels in both the pancreatic parenchyma and duodenal mucosa. There were no findings of residual malignant cells in the wall of the SMV or in the nerve plexus around the SMA. Since the final diagnosis was pT3,(DU+), pN0, cM0, fStage III , we concluded that the R0 resection as complete. Histological therapeutic evaluation with the Evans classification concluded that the disease was Grade III . GEM plus nab-PTX combination chemotherapy could be considered for preoperative chemotherapy, which may allow R0 resection for BR pancreatic cancer.
Collapse
Affiliation(s)
- Takuya Fujimoto
- Dept. of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Yamada T, Kanoh M, Nabe S, Yasuoka T, Suzuki J, Matsumoto A, Kuwahara M, Maruyama S, Fujimoto T, Sakisuka R, Yasukawa M, Yamashita M. Menin Plays a Critical Role in the Regulation of the Antigen-Specific CD8+ T Cell Response upon Listeria Infection. J Immunol 2016; 197:4079-4089. [PMID: 27798149 DOI: 10.4049/jimmunol.1502295] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Accepted: 09/12/2016] [Indexed: 02/06/2023]
Abstract
Menin, a tumor suppressor protein, is encoded by the MEN1 gene in humans. Certain germinal mutations of MEN1 induce an autosomal-dominant syndrome that is characterized by concurrent parathyroid adenomas and several other tumor types. Although menin is also expressed in hematopoietic lineages, its role in CD8+ T cells remains unclear. We generated Meninflox/flox CD4-Cre (Menin-KO) mice by crossing Meninflox/flox mice with CD4-Cre transgenic (Tg) mice to determine the role of menin in CD8+ T cells. Wild-type (WT) and Menin-KO mice were infected with Listeria monocytogenes expressing OVA to analyze the immune response of Ag-specific CD8+ T cells. Menin deficiency resulted in an impaired primary immune response by CD8+ T cells. On day 7, there were fewer Menin-KO OVA-specific CD8+ T cells compared with WT cells. Next, we adoptively transferred WT and Menin-KO OT-1 Tg CD8+ T cells into congenic recipient mice and infected them with L. monocytogenes expressing OVA to determine the CD8+ T cell-intrinsic effect. Menin-KO OT-1 Tg CD8+ T cells were outcompeted by the WT cells upon infection. Increased expression of Blimp-1 and T-bet, cell cycle inhibitors, and proapoptotic genes was observed in the Menin-KO OT-1 Tg CD8+ T cells upon infection. These data suggest that menin inhibits differentiation into terminal effectors and positively controls proliferation and survival of Ag-specific CD8+ T cells that are activated upon infection. Collectively, our study uncovered an important role for menin in the immune response of CD8+ T cells to infection.
Collapse
Affiliation(s)
- Takeshi Yamada
- Department of Infection and Host Defenses, Graduate School of Medicine, Ehime University, Shitsukawa, Toon, Ehime 791-0295, Japan;
| | - Makoto Kanoh
- Department of Infection and Host Defenses, Graduate School of Medicine, Ehime University, Shitsukawa, Toon, Ehime 791-0295, Japan
| | - Shogo Nabe
- Department of Hematology, Clinical Immunology, and Infectious diseases, Graduate School of Medicine, Ehime University, Shitsukawa, Toon, Ehime 791-0295, Japan
| | - Toshiaki Yasuoka
- Department of Obstetrics and Gynecology, Graduate School of Medicine, Ehime University, Shitsukawa, Toon, Ehime 791-0295, Japan
| | - Junpei Suzuki
- Department of Hematology, Clinical Immunology, and Infectious diseases, Graduate School of Medicine, Ehime University, Shitsukawa, Toon, Ehime 791-0295, Japan.,Department of Immunology, Graduate School of Medicine, Ehime University, Shitsukawa, Toon, Ehime 791-0295, Japan; and.,Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime 791-0295, Japan
| | - Akira Matsumoto
- Department of Infection and Host Defenses, Graduate School of Medicine, Ehime University, Shitsukawa, Toon, Ehime 791-0295, Japan
| | - Makoto Kuwahara
- Department of Immunology, Graduate School of Medicine, Ehime University, Shitsukawa, Toon, Ehime 791-0295, Japan; and.,Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime 791-0295, Japan
| | - Saho Maruyama
- Department of Immunology, Graduate School of Medicine, Ehime University, Shitsukawa, Toon, Ehime 791-0295, Japan; and
| | - Takuya Fujimoto
- Department of Infection and Host Defenses, Graduate School of Medicine, Ehime University, Shitsukawa, Toon, Ehime 791-0295, Japan
| | - Ryo Sakisuka
- Department of Infection and Host Defenses, Graduate School of Medicine, Ehime University, Shitsukawa, Toon, Ehime 791-0295, Japan
| | - Masaki Yasukawa
- Department of Hematology, Clinical Immunology, and Infectious diseases, Graduate School of Medicine, Ehime University, Shitsukawa, Toon, Ehime 791-0295, Japan
| | - Masakatsu Yamashita
- Department of Immunology, Graduate School of Medicine, Ehime University, Shitsukawa, Toon, Ehime 791-0295, Japan; and.,Translational Research Center, Ehime University Hospital, Shitsukawa, Toon, Ehime 791-0295, Japan
| |
Collapse
|
34
|
Abstract
Five patients with solitary fatty mass of the pancreas examined with CT and ultrasound (US) were evaluated. The areas of fat replacement were located in the pancreatic neck, body or tail. The size ranged from 4 to 30 mm in the longest diameter. The shape varied from roundish, to ovoid to semicircular, and the contour was universally well defined. The internal structure was homogeneous in 3 patients, but in one case there were thin septa and, in another, a slightly hyperdense part in the peripheral portion. All the masses except the smallest one were in part contact with pancreatic fat. CT showed fat with the same density as the peripancreatic fat and low HU units. The mass was hypoechoic in 2 cases and hyperechoic in one. The masses in the tail of the pancreas were not detected by US.
Collapse
|
35
|
Abstract
The dissolution time of rigid polyurethane foam (PUF) under various glycolysis conditions was examined in a detailed investigation of the glycolysis reactivity of PUF. PUF dissolution depended on the molecular weight of glycol. Dipropylene glycol and tetraethylene glycol dissolved PUF in the shortest time among polypropylene glycols and polyethylene glycols, respectively. PUF dissolution time was reduced to one-half for each 10 C rise in the range of 170–200 C. Also PUF dissolution time was inverselyproportional to KOH (catalyst) concentration. Dibutyltindilaurate concentration had less influence on PUF dissolution time than KOH concentration. Smaller PUF particles dissolved in a shorter time. Especially, the initial glycolysis conversion of PUF was proportional to the total surface area of PUF particles.
Collapse
Affiliation(s)
- M. Murai
- Advanced Technology R&D Center, Mitsubishi Electric Corporation, 8-1-1, Tsukaguchi-Honmachi, Amagasaki-City, Hyogo, 661-8661, Japan
| | | | | | - F. Baba
- Advanced Technology R&D Center, Mitsubishi Electric Corporation, 8-1-1, Tsukaguchi-Honmachi, Amagasaki-City, Hyogo, 661-8661, Japan
| |
Collapse
|
36
|
Fujimura T, Fujimoto T, Kawashima H, Kira T, Hara R, Shimmyo N, Kobata Y, Kido A, Akai Y, Tanaka Y. AB0331 Early Improvement of Musculoskeletal Ultrasound Findings Can Predict Future Clinical Response To Certolizumab Pegol in Patients with Rheumatoid Arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
37
|
Nynca J, Judycka S, Liszewska E, Dobosz S, Arai K, Fujimoto T, Grudniewska J, Ciereszko A. Usefulness of different sugars for cryopreservation of salmon (Salmo salar) semen. Anim Reprod Sci 2016. [DOI: 10.1016/j.anireprosci.2016.03.031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
38
|
Kurebayashi J, Toyama T, Sumino S, Fujimoto T. Abstract P5-12-07: Hormone dynamics, pharmacokinetics, safety and efficacy of leuprorelin acetate 6-month depot formulation and tamoxifen adjuvant endocrine therapy combination in premenopausal patients with hormone receptor-positive breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-12-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Luteinizing hormone-releasing hormone agonist + tamoxifen is standard postoperative adjuvant endocrine therapy for premenopausal patients with hormone receptor-positive breast cancer. Postoperative adjuvant endocrine therapy is now used for a longer period, and the longer-lasting leuprorelin acetate 6-month depot formulation (TAP-144-SR[6M]) is expected to increase patients' quality of life and decrease medical practitioners' burden.
Methods: The hormone dynamics, pharmacokinetics (PK), safety, and efficacy of TAP-144-SR(6M) were compared with those of the 3-month depot formulation (TAP-144-SR[3M]) in a 96-week, phase 3 open-label parallel-group comparison study in premenopausal breast cancer patients after surgery (ClinicalTrial.gov ID: NCT01546649). Inclusion criteria were estrogen receptor (ER) and/or progesterone receptor (PgR) positive; TNM classification of T1-T3, any N, M0; and premenopausal (menstruation confirmed within the previous 12 weeks or both follicle-stimulating hormone [FSH] <40 mIU/mL and estradiol [E2] ≥10 pg/mL at enrollment). Patients were randomized to TAP-144-SR(6M) (6M group [6MG]) or TAP-144-SR(3M) (3M group [3MG]) based on number of axillary lymph node metastases, tumor size, age, ER/PgR status, chemotherapy or not, and study site. The primary endpoint was serum E2 suppression rate based on the menopausal level (≤30 pg/mL) from 4 to 48 weeks after the first administration. Secondary endpoints were serum hormone dynamics, efficacy (disease-free survival [DFS] and distance DFS [DDFS]), PK and safety. The planned number of patients was 164 (82 in each group).
Results: A total of 180 patients were enrolled from Apr 2012 to Feb 2013 and 167 patients were randomized. We compared 83 patients in 6MG (age: mean 44.2; SD 4.90) and 84 patients in 3MG (44.0; 5.18). There were no significant differences in background factors between the groups. 6MG showed non-inferior suppression of serum E2 levels to 3MG (See Table). Serum LH and FSH levels were also decreased. DFSs and DDFSs at 96 weeks after randomization were similar in both groups. A double-peak PK profile and sustainable release of the study drug for 24 weeks were found with 6MG. All-grade adverse events (AEs) occurred in 98.8% and 97.6% and grade 3 or higher AEs in 18.1% and 21.4% with 6MG and 3MG, respectively. There were no significant differences in lumbar spine bone mineral density change rates in both groups.
Table Serum E2 suppression rate based on the menopausal level (≤30 pg/mL) from 4 to 48 weeks after the first administration 6MG (n = 83)3MG (n = 84)Serum E2 suppression rate (%) (95% CI)97.6 (91.565, 99.707)96.4 (89.916, 99.257)6MG − 3MG (95% CI)1.2 (−5.241, 7.806)Note: Noninferiority margin of 10%.
Conclusion: This first clinical study of TAP-144-SR(6M) in premenopausal breast cancer patients showed clinically noninferior serum E2 suppression levels to TAP-144-SR(3M), and no significant safety differences between the groups. TAP-144-SR(6M) was confirmed to have excellent usability in premenopausal breast cancer patients after surgery, and is considered valuable for the appropriate treatment of these patients.
Citation Format: Kurebayashi J, Toyama T, Sumino S, Fujimoto T. Hormone dynamics, pharmacokinetics, safety and efficacy of leuprorelin acetate 6-month depot formulation and tamoxifen adjuvant endocrine therapy combination in premenopausal patients with hormone receptor-positive breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-12-07.
Collapse
Affiliation(s)
- J Kurebayashi
- Kawasaki Medical School, Kurashiki, Japan; Nagoya City University Hospital, Nagoya, Japan; Takeda Pharmaceutical Company Limited, Osaka, Japan
| | - T Toyama
- Kawasaki Medical School, Kurashiki, Japan; Nagoya City University Hospital, Nagoya, Japan; Takeda Pharmaceutical Company Limited, Osaka, Japan
| | - S Sumino
- Kawasaki Medical School, Kurashiki, Japan; Nagoya City University Hospital, Nagoya, Japan; Takeda Pharmaceutical Company Limited, Osaka, Japan
| | - T Fujimoto
- Kawasaki Medical School, Kurashiki, Japan; Nagoya City University Hospital, Nagoya, Japan; Takeda Pharmaceutical Company Limited, Osaka, Japan
| |
Collapse
|
39
|
Jablonska O, Marín A, Kowalewska K, Fujimoto T, Arai K. Short Communication Microsatellite loci in the tetraploid spined loach, Cobitis biwae, and cross-species amplification in four related species. Genet Mol Res 2016; 15:gmr9027. [DOI: 10.4238/gmr.15039027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
40
|
Miyake T, Mashio G, Mori D, Fujimoto T, Yoshinaga M, Yokohara H, Hoshino T, Miyake T, Sato T, Kumagai T. Evaluation of optical and physical properties for initial LiSi press. Dent Mater 2016. [DOI: 10.1016/j.dental.2016.08.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
41
|
Andoh T, Fujimoto T, Suzuki M, Sudo T, Sakurai Y, Tanaka H, Fujita I, Fukase N, Moritake H, Sugimoto T, Sakuma T, Sasai H, Kawamoto T, Kirihata M, Fukumori Y, Akisue T, Ono K, Ichikawa H. Boron neutron capture therapy (BNCT) as a new approach for clear cell sarcoma (CCS) treatment: Trial using a lung metastasis model of CCS. Appl Radiat Isot 2015; 106:195-201. [DOI: 10.1016/j.apradiso.2015.07.060] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2015] [Revised: 06/23/2015] [Accepted: 07/12/2015] [Indexed: 10/23/2022]
|
42
|
Fujimoto T, Nishino S, Shinmura C, Koma Y, Sugiyama M, Uejima S. Clinical study of the modified Caldwell-Luc operation by using 3-D image analysis. Int J Oral Maxillofac Surg 2015. [DOI: 10.1016/j.ijom.2015.08.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
43
|
Shinmura C, Fujimoto T, Nishino S, Koma Y, Sugiyama M, Uejima S. Resistant florid oral papillomatosis: a case report. Int J Oral Maxillofac Surg 2015. [DOI: 10.1016/j.ijom.2015.08.321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
44
|
Fujimoto T, Andoh T, Sudo T, Fujita I, Fukase N, Takeuchi T, Sonobe H, Inoue M, Hirose T, Sakuma T, Moritake H, Sugimoto T, Kawamoto T, Fukumori Y, Yamamoto S, Atagi S, Sakurai Y, Kurosaka M, Ono K, Ichikawa H, Suzuki M. Potential of boron neutron capture therapy (BNCT) for malignant peripheral nerve sheath tumors (MPNST). Appl Radiat Isot 2015; 106:220-5. [PMID: 26278348 DOI: 10.1016/j.apradiso.2015.07.059] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2015] [Revised: 07/30/2015] [Accepted: 07/31/2015] [Indexed: 11/19/2022]
Abstract
Malignant peripheral nerve sheath tumors (MPNST) are relatively rare neoplasms with poor prognosis. At present there is no effective treatment for MPNST other than surgical resection. Nonetheless, the anti-tumor effect of boron neutron capture therapy (BNCT) was recently demonstrated in two patients with MPNST. Subsequently, tumor-bearing nude mice subcutaneously transplanted with a human MPNST cell line were injected with p-borono-L-phenylalanine (L-BPA) and subjected to BNCT. Pathological studies then revealed that the MPNST cells were selectively destroyed by BNCT.
Collapse
Affiliation(s)
- Takuya Fujimoto
- Departments of Orthopaedic Surgery, Hyogo Cancer Center, Kitaouji 13-70, Akashi, Hyogo, 673-0021, Japan.
| | - Tooru Andoh
- Faculty of Pharmaceutical Sciences and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe 650-8586, Japan
| | - Tamotsu Sudo
- Section of Translational Research, Hyogo Cancer Center, Akashi 673-0021, Japan
| | - Ikuo Fujita
- Departments of Orthopaedic Surgery, Hyogo Cancer Center, Kitaouji 13-70, Akashi, Hyogo, 673-0021, Japan
| | - Naomasa Fukase
- Departments of Orthopaedic Surgery, Hyogo Cancer Center, Kitaouji 13-70, Akashi, Hyogo, 673-0021, Japan
| | - Tamotsu Takeuchi
- Department of Immunopathology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan
| | - Hiroshi Sonobe
- Department of Clinical Laboratory, Chugoku Central Hospital, Fukuyama 720-0001, Japan
| | - Masayoshi Inoue
- Department of General Thoracic Surgery, Osaka University, Graduate School of Medicine, Suita 565-0871, Japan
| | - Tkanori Hirose
- Department of Diagnostic Pathology, Hyogo Cancer Center, Akashi 673-0021, Japan
| | - Toshiko Sakuma
- Department of Diagnostic Pathology, Hyogo Cancer Center, Akashi 673-0021, Japan
| | - Hiroshi Moritake
- Division of Pediatrics, University of Miyazaki, Miyazaki 889-1692, Japan
| | - Tohru Sugimoto
- Department of Pediatrics, Saiseikai Shiga Hospital, Ritto 520-3046, Japan
| | - Teruya Kawamoto
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
| | - Yoshinobu Fukumori
- Faculty of Pharmaceutical Sciences and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe 650-8586, Japan
| | | | - Shinji Atagi
- Department of Internal medicine, Kinki-chuo Chest Medical Center, Sakai 591-8025, Japan
| | - Yoshinori Sakurai
- Division of Radiation Life Science, Research Reactor Institute, Kyoto University, Sennan-gun 590-0494, Japan
| | - Masahiro Kurosaka
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
| | - Koji Ono
- Particle Radiation Oncology Research Center, Research Reactor Institute, Kyoto University, Sennan-gun 590-0494, Japan
| | - Hideki Ichikawa
- Faculty of Pharmaceutical Sciences and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe 650-8586, Japan
| | - Minoru Suzuki
- Particle Radiation Oncology Research Center, Research Reactor Institute, Kyoto University, Sennan-gun 590-0494, Japan
| |
Collapse
|
45
|
Sekiguchi M, Fujii T, Kitano M, Matsui K, Hashimoto H, Yokota A, Miki K, Yamamoto A, Fujimoto T, Hidaka T, Shimmyo N, Maeda K, Kuroiwa T, Yoshii I, Murakami K, Ohmura K, Morita S, Kawahito Y, Nishimoto N, Mimori T, Sano H. AB0472 Predicting Factors Associated with Sustained Clinical Remission by Abatacept are Different Between in Younger and Elderly Patients with Biologic-Naïve Rheumatoid Arthritis (Abroad Study). Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2693] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
46
|
Hara R, Tanaka Y, Fujimoto T, Akai Y, Kobata Y, Kido A, Shimmyo N, Fujimura T. AB0310 Prognostic Factor for Forefoot Deformity in Early Rheumatoid Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.6432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
47
|
Fujimoto T, Abe T, Okabe Y, Johshima K, Fukuyama K, Noda T, Shimoike N, Maekawa H, Tada S, Iwata T, Yoshimoto Y, Fujikawa T, Tanaka A. [A case of adenocarcinoma occurring in the bladder mucosa after a surgical operation for colovesical fistula]. Gan To Kagaku Ryoho 2014; 41:2462-2464. [PMID: 25731558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
We report a case of adenocarcinoma occurring in the bladder mucosa 6 years after a surgical operation for colovesical fistula due to colonic diverticulitis of the sigmoid colon. The patient was a 76-year-old woman who had undergone a sigmoidectomy and ligation of the colovesical fistula at the age of 70 years. She presented with a complaint of gross hematuria. Cystoscopy and computed tomography revealed bladder cancer at the site of the original colovesical fistula surgery. She underwent transurethral resection of the bladder tumor. Histopathological findings revealed intestinal adenocarcinoma in the urinary bladder. A radical partial cystectomy was subsequently performed because of a positive and involved margin. This tumor may have originated from the bladder mucosa and then replaced by intestinal metaplastic cells that originated from the same initiating event.
Collapse
|
48
|
Umezawa R, Jingu K, Sugawara T, Kubozono M, Abe K, Fujimoto T, Yamamoto T, Ishikawa Y, Kozumi M, Kadoya N, Takeda K, Matsushita H. Long-Term Results of Chemoradiation Therapy for Stage II-III Thoracic Esophageal Cancer: Comparison of 3 Protocols. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
49
|
Fujimura T, Fujimoto T, Hara R, Kondo S, Shimmyo N, Kobata Y, Kido A, Akai Y, Tanaka Y. FRI0277 Predicting Future Response to Tumor Necrosis Factor Inhibitors by the Distribution of Affected Joints in Rheumatoid Arthritis Patients. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1980] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
50
|
Kido A, Akahane M, Hara R, Shimizu T, Nakano K, Kobata Y, Fujimura T, Shinmyo N, Akai Y, Fujimoto T, Tanaka Y. AB0802 A Patients Preference Survey for Osteoporosis Medication on 679 Patients: Monthly Drug Regimen Can be the Best for the Adherence. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|